New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 5, 2014
05:42 EDTJNJ, SYK, SNN, ZMH, MDTMedtronic offer for Smith & Nephew may bring bidding war, says Wells Fargo
Wells Fargo believes a Medtronic (MDT) takeover offer for Smith & Nephew (SNN) would make strategic and financial sense. However, Wells cautions that Smith & Nephew's "relatively small" share in hip and knee implants could put Medtronic at a competitive disadvantage to larger ortho players Johnson & Johnson (JNJ) and Zimmer (ZMH). The firm thinks a potential offer from Medtronic may prompt Stryker (SYK) to reconsider Smith & Nephew, potentially resulting in a bidding war.
News For MDT;SNN;JNJ;ZMH;SYK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 27, 2015
06:59 EDTMDTMedtronic volatility flat into Q2 and outlook
Subscribe for More Information
November 24, 2015
08:31 EDTMDTMedtronic remains a top tier performer in Med Device space, says Cowen
Subscribe for More Information
November 20, 2015
10:52 EDTJNJFDA approves new oral medication to treat multiple myeloma
Subscribe for More Information
08:28 EDTSNNSmith & Nephew management to meet with Jefferies
Subscribe for More Information
05:22 EDTMDTStocks with implied volatility movement; MDT UNH
Stocks with implied volatility movement; Medtronic (MDT) 25, UnitedHealth (UNH) 30 according to iVolatility.
November 18, 2015
08:11 EDTJNJIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
08:11 EDTJNJAduro Biotech receives milestone payment from Janssen
Aduro Biotech (ADRO) announced that it has received a milestone payment from Janssen Biotech (JNJ) for Aduro's submission of an Investigational New Drug, or IND, Application to the FDA for ADU-741, a LADD immunotherapy product candidate for the treatment of prostate cancer. The IND will enable Janssen, Aduro's license partner for ADU-741, to initiate a multi-center Phase 1 trial to evaluate the safety and immunogenicity of intravenous administration of ADU-741 in patients with metastatic castration-resistant prostate cancer.
November 17, 2015
10:02 EDTSYKHigh option volume stocks
Subscribe for More Information
09:14 EDTMDTMedtronic announces FDA approval, launch of MyCareLink Smart Monitor
Subscribe for More Information
November 16, 2015
14:38 EDTJNJGenmab confirms FDA approval of Darzalex
Subscribe for More Information
13:09 EDTJNJFDA approves Darzalex to treat multiple myeloma
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use